Baird: Not surprised by upside pre-announcement from Tandem Diabetes

After Tandem Diabetes pre-announced better than expected Q3 revenue and an updated full-year view that implies Q4 revenue largely in line with consensus estimates, Baird analyst Jeff Johnson said he was not surprised by the upside and expects the company’s solid fundamentals to persist as U.S. growth remains strong and international revenue starts to contribute. However, he thinks the current valuation reflects this strength and maintains a Neutral rating and $47 price target on Tandem Diabetes shares.
https://thefly.com/landingPageNews.php?id=2795255